Keren Sinik

Title: Keren Sinik: Innovator in Antibody Technology

Introduction

Keren Sinik is a notable inventor based in Ramat-Yishai, Israel, recognized for his contributions to the field of antibody technology. With a total of three patents to his name, Sinik has made significant advancements in the development of affinity binding entities that have important applications in diagnostics and therapy.

Latest Patents

Sinik's latest patents include innovative compositions that feature affinity entities comprising a TCR-like antibody binding domain. These entities exhibit high affinity and fine specificity, particularly binding to HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP, or HLA-A2/TyrD+ cells. Such compositions are poised to enhance diagnostic and therapeutic strategies in cancer treatment. Another significant patent involves antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA-restricted manner, specifically targeting HLA-A2/TyrD369-377. This patent also provides complementary determining region (CDR) sequences of heavy and light chain antibodies, along with methods for utilizing these antibodies in cancer therapy.

Career Highlights

Throughout his career, Keren Sinik has worked with various companies, including Adicet Therapeutics, Inc. His work has focused on the intersection of immunology and therapeutic development, contributing to advancements that have the potential to improve patient outcomes in cancer treatment.

Collaborations

Sinik has collaborated with notable colleagues, including Mira Peled Kamar and Galit Denkberg, who have contributed to his research endeavors. These collaborations have fostered an environment of innovation and shared expertise in the field of antibody technology.

Conclusion

Keren Sinik's work in the development of affinity binding entities and antibodies represents a significant contribution to the field of immunotherapy. His patents and collaborations highlight the importance of innovation in addressing complex medical challenges.